Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.
Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Brian Yang
China's third-ranked health official Ma Xiaowei has been promoted to the top position, leading an agency transforming itself from treating diseases to health policy-making against a backdrop of a fast-aging population, emerging data and new AI technologies.
Takeda appoints a new chief financial official, the third in recent years, and a new consumer health CEO, while WuXi NextCode taps its COO to lead the genomics firm. Senior executives changes also take place at PAREXEL, Asahi Kasei Pharma, and Actelion Japan.
China proposes to merge its top drug and device regulator into a new combined body and create a medical reimbursement agency in moves directed at strengthening regulatory oversight.
Leveraging the internet and big data to improve healthcare, regulatory efficiency and cancer treatment are among the priorities singled out by the Chinese Premier at the annual National People's Congress meeting. Some delegates say drug approval and coverage challenges remain, while industry observers point to commercial insurance as a solution to drive the specialty market such as cancer care.
The Shanghai-based biotech startup Harbour Biomed hopes overseas licensing will propel it towards an initial offering in the US, following in the footsteps of a successful approach pioneered by BeiGene.